Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.
These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.
OYLER JOHN reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that Chief Executive Officer John Oyler received two equity awards of Ordinary Shares as compensation. On March 6, 2026, he was granted 326,976 shares underlying earned performance share units that vest in 2027, and an additional 117,936 shares underlying earned performance share units that vest in 2028, in each case at no cash cost to him and subject to his continued service, with potential accelerated vesting upon a change of control or certain termination events. Following these awards, Oyler directly holds 5,609,275 Ordinary Shares. The filing also notes several indirect holdings in trusts and an LLC where he disclaims beneficial ownership, plus shares held for his benefit in a Roth IRA account.
Lee Chan Henry reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards on ordinary shares. These awards cover 65,390 and 29,874 shares underlying earned performance share units that vest in 2027 and 2028, subject to continued service. Following these grants, Henry directly holds 318,370 ordinary shares.
BeOne Medicines Ltd. reported that President and Global Head of R&D Wang Lai received equity compensation in the form of performance share units on ordinary shares. The grants cover 112,606 shares vesting in 2027 and 55,029 shares vesting in 2028, subject to continued service and possible accelerated vesting upon certain termination events. After these awards, Wang directly holds 1,619,059 ordinary shares.
He also has indirect exposure to 601,965 ordinary shares held by Wang Holdings LLC, for which he disclaims beneficial ownership, and an indirect economic interest in RMB Shares acquired through an employee participation plan, over which he has no voting or dispositive power.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported equity awards and updated share holdings. He received two grants classified as acquisitions of ordinary shares, covering 168,922 and 78,624 shares tied to performance share units. These earned units will vest in 2027 and 2028 if he continues serving the company, with unvested amounts eligible for accelerated vesting upon certain termination events. Following these awards, he directly holds 1,216,524 ordinary shares, 12,365 American Depositary Shares (ADSs) directly, and 4,000 ADSs indirectly through his wife. Each ADS represents 13 ordinary shares.
BeOne Medicines Ltd. reported that Chief Financial Officer Aaron Rosenberg received equity compensation in the form of ordinary shares linked to performance share units. On March 6, 2026, he was granted 79,014 ordinary shares underlying earned performance share units that are scheduled to vest in 2027, and an additional 40,573 ordinary shares underlying earned performance share units scheduled to vest in 2028.
All of these earned performance share units will vest only if Rosenberg continues to provide service to the company through the respective vesting dates, with unvested awards eligible for accelerated vesting upon certain termination events. Following these awards, his direct ownership increased to 334,919 ordinary shares, reflecting a compensation-related acquisition rather than an open-market purchase.
BeOne Medicines Ltd. reports a strong 2025 with rapid growth and first-time profitability driven by its global oncology franchise. The company generated approximately $5.3 billion in total global revenue in 2025, up about 40.2% year over year, and produced net income of $286.9 million.
Operations generated $1.1 billion of net cash from operating activities and free cash flow of $941.7 million, supporting a year-end balance of $4.5 billion in cash and cash equivalents and $1.0 billion of debt. Product revenue grew 39.8% from 2024.
Growth is led by oncology blockbusters BRUKINSA, a BTK inhibitor with about $3.9 billion in 2025 sales and approvals in over 75 markets, and PD‑1 antibody TEVIMBRA, which is approved in more than 50 markets and broadly listed on China’s NRDL. The company is building a “foundational” chronic lymphocytic leukemia franchise around BRUKINSA, BCL2 inhibitor sonrotoclax, and BTK degrader BGB‑16673, while advancing a deep solid-tumor pipeline and over 70 preclinical programs.
BeOne Medicines delivered a strong 2025, with total revenue rising 40% to $5.34 billion and fourth-quarter revenue up 33% to $1.50 billion. Product revenue made up 99% of the total.
Flagship BTK inhibitor BRUKINSA generated $3.9 billion in 2025 sales, up 49%, including $2.8 billion in the U.S. TEVIMBRA added $737 million, up 19%, while Amgen in-licensed products contributed $486 million, up 33%.
GAAP net income improved to $286.9 million from a $644.8 million loss, and free cash flow reached $941.7 million. For 2026, BeOne guides total revenue to $6.2–$6.4 billion, GAAP operating income of $700–$800 million, and non-GAAP operating income of $1.4–$1.5 billion, with gross margin expected in the high-80% range.
ONC has a shareholder filing a notice to sell 4,676 American Depositary Shares (ADS). The shares are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value listed as 1,619,672.88.
The ADS were acquired on 02/04/2026 through an exercise of stock options, paid in cash on the same date. The filing also lists recent Rule 10b5-1 sales for Chan Lee, including 996 ADS sold on 11/12/2025 for 347,770.00. The seller represents they are not aware of any undisclosed material adverse information about ONC.
BeOne Medicines Ltd. insider Lee Chan Henry, SVP and General Counsel, reported option exercises and an automatic sale of American Depositary Shares (ADS). On January 7, 2026, Henry exercised three share options covering 2,626, 3,458 and 2,548 Ordinary Shares at exercise prices of $14.96, $16.41 and $12.23 per Ordinary Share. These exercises resulted in issuances of 202, 266 and 196 ADS at prices of $194.47, $213.32 and $159.03 per ADS. The filing also reports a sale of 664 ADS at $331.76 per ADS, carried out under a Rule 10b5-1 trading plan adopted on May 14, 2025. After these transactions, Henry reported 223,106 Ordinary Shares beneficially owned directly and continued holdings of multiple option grants with staggered vesting schedules.